LENZ
LENZ Therapeutics, Inc.
$5.59
-0.20 (-3.45%)
At close · Jul 10
Market Cap
$175.27M
Shares
31,354,394
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$5.59
Open$5.85
Day$5.34–5.86
52W$5.23–50.40
Avg vol 30d810K
Short int10.4M · 33.3% float · 11.0d
Short vol46%
Last earningsMay 11, 2026
DataJun 2021–Jul 2026
Filing10-Q · May 11
Up next
Next earnings call
Aug 13, 2026
Est · unconfirmed
· in 5 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 11, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 15 · calm
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−68%
below
Price vs 50-day avg
−22%
below
RSI (14)
37
neutral
MACD trend
Positive
52-week position
1%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−15%
trailing
6-month return
−69%
trailing
YTD return
−65%
this year
Relative strength
−78%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $7 › 200d $18 — 200d above 50d
Institutional flow
Accumulating
3 of 146 funds reported for Jun 30 · net +222 sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
33.27% of float · ▲ +0.5% MoM · 11.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
146 holders — mid 2-yr range
Squeeze score
76
high risk · 0–100
Fundamentals
EPS growth
−22%
Y/Y
Free cash flow
$-70.0M
Balance sheet
$25.2M
net cash
Quant / Vol
risk profile
Volatility
80%
annualized · 1-yr
Max drawdown
−89%
past year
ATR
8.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−68%
Bearish
Price vs 50-day avg
−22%
Bearish
RSI (14)
37
Neutral
MACD trend
Positive
Bullish
52-week position
1%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $7 › 200d $18 — 200d above 50d
Institutional flow
Accumulating
3 of 146 funds reported for Jun 30 · net +222 sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
33.27% of float · ▲ +0.5% MoM · 11.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
146 holders — mid 2-yr range
Price context
position in its 52-week range
52-wk low $5
Now $6 · 1%
52-wk high $50
vs 200-day avg -68%
vs 50-day avg -22%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| daily doses sold from launch through Q1 2026 | 1.2M | launch through Q1 2026 | — |
| paid prescriptions | 25,000 | Q1 2026 | — |
| paid prescriptions filled from launch through Q1 2026 | 46,000 | launch through Q1 2026 | — |
| filled prescriptions | 20,000 | Q4 2025 | — |
| prescriptions filled | 20,000 | Q4 2025 | — |
| unique prescribing ECPs | 6,500 | Q4 2025 | — |
| VIZZ net product revenue | $1.6M | Q4 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
LENZ
this stock
LENZ Therapeutics, Inc.
|
$175.27M | -65.1% | — | — | 33.3% |
|
ONC
BeOne Medicines Ltd.
|
$431.70B | -1.7% | +22179.2% | 878.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$123.19B | +7.1% | +46.2% | 28.8 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.67B | -13.8% | +20.8% | 16.2 | 3.3% |
|
ARGX
Argenx SE
|
$54.85B | +4.4% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| LENZ | -5.1% | -15.1% | -69.2% | -1.6% | -65.1% |
| SPY | +1.4% | +4.1% | +9.1% | +1.1% | +10.7% |
| vs SPY | -6.5% | -19.1% | -78.2% | -2.7% | -75.8% |